Foresite Capital is a growth equity firm specializing in healthcare. They have recently named Molly He, Ph.D. as their venture partner. Dr. He previously worked at Illumina as a senior director and has over fifteen years’ experience in genomic and pharmaceutical development and research.
Dr. He is considered one of the most respected scientific researchers in the field of next generation sequencing. Foresite Capital is thrilled to have Dr. He on their team and believes she will be an invaluable resource. Foresite is in the process of expanding and diversifying their portfolio.
During the time Dr. He worked at Illumina as a scientific researcher she was responsible for improvements to the company’s protein reagent innovations. Previously she headed the protein sciences department at Pacific Biosciences. She was responsible for developing protein reagents for single molecular sequencing chemistry. In her earlier career, Dr. He was in the pharmaceutical industry for ten years. Her target was immune diseases and cancer.
Dr. He attended Nankai University where she received her Bachelor’s degree. She earned her Ph.D. in protein biophysics at the University of California. She has written over twenty published papers and has over twenty issued patents and patent applications and learn more about Jim.
Dr. He stated Foresite has an incredible reputation and have invested in healthcare companies that are innovative and exciting. She feels honored to become a part of the team growing the sequencing portfolio for the company. She believes it is this area that will be responsible for the future breakthroughs in drug discoveries and clinical research.
Foresite Capital works with healthcare leaders and services all healthcare sectors. They are based out of San Francisco, have additional offices in New York and work in both the public and private markets and more information click here.
Foresite Capital Management was found by Dr. Jim Tananbaum who remains the company’s CEO. He has successfully led 21 healthcare companies. These include Jazz Pharmaceuticals, Amerigroup and Amira Pharmaceuticals. Dr. Tananbaum previously held management positions and founded GelTex Pharmaceuticals and Theravance.
Dr. Jim Tananbaum received his M.D. from Harvard Medical School and earned his M.B.A. at Harvard Business School. He also has a B.S.E.E. and a B.S. from Yale University. He served on the visiting committees or the advisory boards for the Yale School of Engineering and the Harvard-MIT HST program.